Axogen, Inc. reported significant financial results for the first quarter of 2026, with revenues reaching $61.5 million, a 26.6% increase from $48.6 million in the same period last year. The company's gross profit also saw a substantial rise, climbing to $46.2 million, up 32.2% from $34.9 million in the prior year. However, Axogen recorded a net loss of $19.6 million, compared to a loss of $3.8 million in the first quarter of 2025. This increase in net loss was primarily attributed to a $16.8 million loss on the extinguishment of debt, following the repayment of its Credit Facility.
The company’s operational metrics reflected a strong performance, with a gross margin of 75.2%, up from 71.9% in the previous year, driven by lower inventory write-offs and reduced shipping costs. Axogen's total costs and expenses increased to $49.0 million, primarily due to higher sales and marketing expenses, which rose to $28.6 million from $21.0 million, as well as increased research and development costs. The company’s employee headcount has also grown, contributing to higher compensation costs.
Strategically, Axogen has made notable advancements, including the successful completion of a public offering that raised $133.3 million, which was used to fully repay its Credit Facility. The company also received positive coverage decisions from major insurers, including Cigna and Elevance Health, enhancing its market position. Additionally, the Centers for Medicare & Medicaid Services (CMS) introduced a new Level 3 Nerve Procedure Code, which is expected to increase reimbursement rates for its Avance product.
Looking ahead, Axogen aims to deepen its presence in high-potential accounts, particularly in Level 1 trauma centers and academic hospitals. The company anticipates that its existing cash and cash equivalents, along with revenues from product sales, will support its operations for at least the next twelve months. However, management acknowledges potential risks from macroeconomic factors, including market volatility and geopolitical tensions, which could impact future performance.
About Axogen, Inc.
Axogen, Inc. specializes in the development and commercialization of regenerative medicine technologies for peripheral nerve repair and regeneration. Its product portfolio includes biologically active nerve allografts, extracellular matrix-based nerve connectors, protectors, caps, and soft tissue matrices used by surgeons to treat nerve injuries from trauma, surgery, and compression. Serving primarily hospitals and surgeons in the U.S. and select international markets, Axogen offers clinically validated, off-the-shelf solutions that improve nerve function and patient quality of life.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.